15 Best Biotech Stocks to Buy According to Billionaires

2. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Billionaires: 15 

Dollar Value of Billionaire Holdings: $1,191,063,655

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and markets specialized therapies for rare genetic diseases, focusing on enzyme replacement treatments and other biopharmaceuticals. The company stands out for its dedication to rare diseases, successfully bringing eight breakthrough medicines to market, including treatments for achondroplasia, severe hemophilia A, and lysosomal storage diseases.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) delivered strong financial results for Q4 2024, showing solid growth across key areas. Its total revenue rose 18% to $2.85 billion for the year, with Q4 revenue up 16% to $747 million. VOXZOGO sales surged 56% to $735 million, reflecting increased adoption for achondroplasia, while enzyme therapies contributed over $1.9 billion, growing 12% from 2023.

The corporation’s profitability improved significantly, with the non-GAAP operating margin expanding to 28.6% for the year and 31.1% in Q4. Earnings per share (EPS) jumped 69% to $3.52, and Q4 EPS rose 88% to $0.92, which was driven by revenue growth and operational efficiency. Operating cash flow also saw a massive 260% increase to $573 million, providing financial flexibility for future investments.

Looking ahead, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) expects 2025 revenue between $3.1 billion and $3.2 billion, with a 10% growth outlook. Margins are projected to improve further, with non-GAAP operating margins between 32%-33% and EPS between $4.20 and $4.40. This indicates continued efficiency and profitability.

Beyond financials, the business is advancing its drug pipeline, with early clinical data for BMN 351 (Duchenne Muscular Dystrophy) and BMN 333 expected later this year. These developments could drive further growth and impact the stock positively.